Recombinant tissue plasminogen activator for acute ischemic stroke

Saudi Medical Journal

Volumn 23, Issue 1, 2002, Pages 13-19

  Al Buhairi, Amira R ^a   Jan, Mohammed M ^b  

^a KING KHALID NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Infarction; Recombinant tissue plasminogen activator; Stroke

Indexed keywords

ALTEPLASE; HEPARIN; PLACEBO;

ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ARTERY; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DEFICIENCY; OCCLUSIVE CEREBROVASCULAR DISEASE; RISK FACTOR; STROKE; SYMPTOMATOLOGY; UNITED STATES;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EMERGENCY TREATMENT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0036185130     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Intra-arterial prouroKinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial
2. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
3. Thrombolytic therapy in acute ischemic stroke: An update
4. Thrombolytic intervention in acute thrombotic and embolic stroke
5. Peripheral and central nervous system drug advisory committee meeting. Activase, Alteplase recombinant for acute ischemic stroke: Efficacy supplement
6. Tissue plasminogen activator for acute ischemic stroke
7. Guideline for thrombolytic therapy for acute ischemic stroke: A statement for health care professional from the special writing groups of stroke council, American Heart Association
8. Canadian guidelines for intravenous thrombolytic treatment in acute stroke: A consensus statement of the Canadian stroke consortium
9. Intravenous tissue plasminogen activator for acute ischemic stroke
10. Intravenous rt-Pa therapy for stroke in clinical practice: A multi-center evaluation of outcome
11. Stroke treatment in the community. Intravenous rt-PA in clinical practice
12. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke
13. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischemic stroke (ECASS II)
14. Recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptoms onset
15. Improved reliability of the NIH stroke scale using video training
16. Functional evaluation: The Barthel Index
17. Interobserver agreement for the assessment of handicap in stroke patients
18. Observer variability in assessing impaired consciousness and coma
19. Trends in protecting ischemic brain
20. Further evolution toward effective therapy for acute ischemic stroke
21. Type and extent of hemispheric brain infarction in clinical outcome in early and middle cerebral artery recanalization
22. Dose arterial recanalization improve outcome in carotid territory stroke?
23. Intravenous thrombolysis for acute ischemic stroke